Published in Women's Health Weekly, March 11th, 2000
The study is designed to demonstrate the bone-building and fracture-reducing power of the drug. It will be a multi-center trial of about 2,000 post-menopausal women who have osteoporosis. Dosing will last for 18 months, with the drug compared to placebo.
ALX1-11 is an injectable version of human parathyroid hormone, a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly